UBS Group
GLSI icon

UBS Group’s Greenwich LifeSciences GLSI Stock Holding History

UBS Group’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$507K Buy
21,116
+15,036
+247% +$392K ﹤0.01% 6075
2025
Q4 		$128K Buy
6,080
+1,974
+48% +$20.8K ﹤0.01% 6785
2025
Q3 		$40.9K Buy
4,106
+2,261
+123% +$25.5K ﹤0.01% 7704
2025
Q2 		$16.7K Sell
1,845
-1,351
-42% -$12.8K ﹤0.01% 8557
2025
Q1 		$30.5K Sell
3,196
-3,361
-51% -$40.8K ﹤0.01% 7932
2024
Q4 		$73.6K Buy
6,557
+3,750
+134% +$50.2K ﹤0.01% 7062
2024
Q3 		$40.3K Buy
2,807
+1,000
+55% +$14.8K ﹤0.01% 6957
2024
Q2 		$31.2K Buy
1,807
+1,405
+350% +$20.5K ﹤0.01% 7034
2024
Q1 		$8.02K Sell
402
-1,438
-78% -$17.7K ﹤0.01% 7349
2023
Q4 		$19.4K Buy
1,840
+1,839
+183,900% +$18.4K ﹤0.01% 7123
2023
Q3 		$9 Sell
1
-227
-100% -$2.13K ﹤0.01% 9229
2023
Q2 		$2.2K Buy
228
+227
+22,700% +$2.54K ﹤0.01% 7794
2023
Q1 		$14 Sell
1
-723
-100% -$11.5K ﹤0.01% 9445
2022
Q4 		$11K Sell
724
-1,085
-60% -$12.4K ﹤0.01% 8447
2022
Q3 		$17K Buy
1,809
+939
+108% +$8.69K ﹤0.01% 7591
2022
Q2 		$7K Buy
870
+45
+5% +$516 ﹤0.01% 8486
2022
Q1 		$16K Sell
825
-1,939
-70% -$39.2K ﹤0.01% 7736
2021
Q4 		$67K Sell
2,764
-1,546
-36% -$51.7K ﹤0.01% 6659
2021
Q3 		$168K Buy
4,310
+3,550
+467% +$148K ﹤0.01% 5449
2021
Q2 		$34K Buy
760
+451
+146% +$17.1K ﹤0.01% 6796
2021
Q1 		$11K Sell
309
-571
-65% -$19.4K ﹤0.01% 7856
2020
Q4 		$32K Buy
880
+603
+218% +$8.79K ﹤0.01% 6574
2020
Q3 		$1K Buy
+277
New +$1.32K ﹤0.01% 7789

Other funds holding GLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

UBS Group's GLSI Position: Q1 2026 in Review

UBS Group increased its Greenwich LifeSciences (GLSI) stake by 247% in Q1 2026, buying an estimated $392K and bringing the position to 21,116 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #6075.

UBS Group first reported a position in GLSI in Q3 2020 and has held it in 23 quarters since. 64 funds tracked by Wall St. Rank hold GLSI as of Q1 2026.

  • UBS Group held 21,116 shares of Greenwich LifeSciences worth $507K as of Q1 2026.
  • UBS Group bought 15,036 Greenwich LifeSciences shares in Q1 2026, an estimated $392K.
  • Greenwich LifeSciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6075 holding.
  • UBS Group first reported a position in Greenwich LifeSciences in Q3 2020 and has held it in 23 quarters since.
  • 64 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.